Paroxysmal supraventricular tachycardia secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 2: Line 2:
{{Paroxysmal supraventricular tachycardia}}
{{Paroxysmal supraventricular tachycardia}}
{{CMG}}; {{AE}}{{Noha}}
{{CMG}}; {{AE}}{{Noha}}
==Overview==
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
==Secondary Prevention==
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
*[Strategy 1]
*[Strategy 2]
*[Strategy 3]
==References==
{{Reflist|2}}
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Cardiovascular diseases]]
[[Category:Cardiovascular diseases]]

Latest revision as of 03:06, 24 May 2020

Paroxysmal supraventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paroxysmal supraventricular tachycardia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paroxysmal supraventricular tachycardia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paroxysmal supraventricular tachycardia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paroxysmal supraventricular tachycardia secondary prevention

CDC on Paroxysmal supraventricular tachycardia secondary prevention

Paroxysmal supraventricular tachycardia secondary prevention in the news

Blogs on Paroxysmal supraventricular tachycardia secondary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Paroxysmal supraventricular tachycardia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Noha Elzeiny, M.B.B.Ch, M.Sc.[2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include:

  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]

References


Template:WH Template:WS